Pharmaceuticals

A new partnership leverages advanced AI and metabolomics to find novel drug targets for rare metabolic disorders, offering new hope for millions worldwide.

As Akebia heads to a major conference, investors watch its Vafseo launch, new rare disease pipeline, and path to profitability. Here's what's at stake.

A novel drug delivery system could revolutionize Alzheimer's treatment, and Acumen Pharmaceuticals is leading the charge with its targeted therapy.

As SIGA prepares to unveil its 2025 financials, investors are focused on the future of its Tpoxx contracts and its role in global biodefense strategy.

With promising clinical data for its heart disease treatments, Lexeo Therapeutics aims to capture investor attention at the upcoming Leerink conference.

Former Novo Nordisk CSO Marcus Schindler joins Cradle, validating AI's role in accelerating drug discovery and reshaping traditional pharmaceutical R&D.

After a kidney trial setback, CalciMedica's lead drug Auxora shows strong promise for acute pancreatitis, but a tight cash runway looms over its future.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

Esperion's $75M+ deal for Corstasis and its novel nasal diuretic, Enbumyst, targets a $4B market and a new era of at-home edema management.

Greenwich LifeSciences' Phase III trial for its GLSI-100 immunotherapy is enrolling patients faster than ever, with early data echoing past success.

A novel CRISPR-based therapy safely targets deadly E. coli in the gut, showing promise in the fight against antibiotic resistance and for protecting cancer patients.

Peli BioThermal and Polar Group partner to upgrade Brazil's pharma logistics, tackling a booming market and ensuring safer delivery of advanced medicines.

Popular weight-loss drugs are linked to fewer ER visits for chronic migraine, a new study finds, sparking hope and questions about a new treatment frontier.

A promising oral therapy for Huntington's disease has been deemed eligible for accelerated review in Australia, offering new hope for a breakthrough.

A next-gen drug for chronic hives shows superior, faster results than the long-standing standard of care, heralding a potential shift in allergy treatment.

As SAB Biotherapeutics prepares for key investor talks, a closer look reveals its novel T1D therapy and the unique bovine tech aiming to change treatment.

A new study aims to confirm a novel immunotherapy's dramatic results in colorectal cancer, offering hope for patients with limited treatment options.

With 14% growth, strategic acquisitions, and major AI advancements, Real Chemistry is redefining healthcare commercialization on its 25th anniversary.

Halia Therapeutics is betting on a novel target to fight chronic inflammation. At a key summit, it will pitch its unique approach for cancer, obesity, and Alzheimer's.

DRI Healthcare's strategic C$109M debt swap lowers interest costs, extends maturity, and signals strong investor confidence to fuel its acquisition pipeline.